Site-specific PKM2 phosphorylation in Cancer: A systematic review of its role in metabolic plasticity and precision therapy

Keywords

Precision oncology, Pyruvate kinase M2 (PKM2), Site-specific phosphorylation, Cancer metabolism, Tumor growth and therapy resistance, Metabolic plasticity

Abstract

Pyruvate Kinase M2 (PKM2), a central glycolytic enzyme, plays a key role in tumour metabolism and growth. Its activity is regulated via site-specific phosphorylation at Tyr105, Ser37, and Thr454, affecting metabolic plasticity, tumour progression, and therapy resistance. This systematic review consolidates evidence on PKM2 phosphorylation in cancer, its metabolic and signalling roles, and potential as a biomarker and therapeutic target in precision oncology. A systematic search of PubMed, Scopus, and EMBASE was conducted per PRISMA 2020 guidelines. Studies examining site-specific PKM2 phosphorylation and its functional or clinical relevance in cancer were included. Data extraction focused on phosphorylation sites, signalling pathways, metabolic and tumour effects, and therapeutic applications. Fifty-eight studies met inclusion. Tyr105, Ser37, and Thr454 influenced PKM2 activity, localization, and oncogenic interactions, enhancing glycolysis, tumour plasticity, growth, and therapy resistance. Site-specific PKM2 phosphorylation regulates metabolism and tumour behaviour, highlighting its value as a biomarker and therapeutic target.

Site-specific PKM2 phosphorylation in Cancer: A systematic review of its role in metabolic plasticity and precision therapy

Mohammed Merae Alshahrani*

Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran, 61441, Saudi Arabia

***Corresponding Author**: Mohammed Merae Alshahrani, Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran, 61441, Saudi Arabia, mmalshahrani@nu.edu.sa, https://orcid.org/0000-0002-9387-5492

Abstract

Pyruvate Kinase M2 (PKM2), a central enzyme in glycolysis, plays a key role in tumour metabolism and growth. Its activity is tightly regulated through site-specific phosphorylation at residues such as Tyr105, Ser37, and Thr454. These modifications influence metabolic plasticity, tumour progression, and therapy resistance. This systematic review consolidates current evidence on PKM2 phosphorylation in cancer, its metabolic and signalling implications, and potential as a biomarker and therapeutic target in precision oncology. A systematic search of PubMed, Scopus, and EMBASE was conducted per PRISMA 2020 guidelines. Studies investigating site-specific PKM2 phosphorylation and its functional or clinical relevance in cancer were included. Data extraction focused on phosphorylation sites, signalling pathways, metabolic and tumour-related effects, and therapeutic applications. Study quality and bias risk were assessed using standardized tools. Fifty-eight studies met the inclusion. Tyr105, Ser37, and Thr454 were the most frequently reported phosphorylation sites, each significantly influencing PKM2 activity, localization, and oncogenic interactions. Their modification consistently enhanced glycolysis, plasticity, tumour growth, and resistance to therapy across cancers. Site-specific PKM2 phosphorylation regulates metabolism and tumour behaviour, underscoring its value as a biomarker and therapeutic target for precision-based cancer management.

Keywords: Pyruvate kinase M2 (PKM2), Site-specific phosphorylation, Cancer metabolism, Tumor growth and therapy resistance, Metabolic plasticity, Precision oncology.

Introduction

Cancer cells undergo radical metabolic reprogramming to fuel fast growth, withstand hypoxia, as well as respond to shifts in nutrients, as well as evade therapeutic pressure. Typical of the reprogramming is upregulated aerobic glycolysis, or the Warburg effect, so that cancer cells may meet their biosynthetic as well as energy needs [1, 2]. Pyruvate kinase M2 (PKM2), the glycolysis rate-controlling enzyme, is the linchpin. Characteristic of PKM2, compared to its isoform PKM1, is the ability to exist in multiple conformations, so that it must switch between energy output as well as anabolic metabolism [3]. Furthermore, PKM2 is localized to the nucleus, where regulation of gene expression as well as oncogenic signal support takes place [4]. Recent findings postulate that post-translational modifications (PTMs), most notably site-specific phosphorylation, substantially influence PKM2's enzymatic activity, cellular localization, as well as non-metabolic activities [4, 5]. Phosphorylation on specific sites including Tyr105, Ser37, as well as Thr454 has been postulated to foster metabolic plasticity, tumor growth, chemotherapy resistance, as well as immune evasion [6]. Because of these pleiotropic activities, phosphorylated PKM2 has come into the spotlight as both a biomarker as well as therapeutic target during the practice of precision oncology.

Despite a growing body of literature, there is currently no comprehensive synthesis of evidence focusing specifically on site-specific PKM2 phosphorylation and its implications in cancer metabolism and targeted therapy. To address this gap, the present systematic review aims to summarize current evidence on site-specific phosphorylation of PKM2 across different cancer types; evaluate the functional impact of specific phosphorylation events on PKM2-mediated metabolic reprogramming and oncogenic signaling; assess the clinical relevance of phosphorylated PKM2 as a diagnostic, prognostic, or predictive biomarker; and explore its potential as a therapeutic target within the framework of precision medicine. By consolidating these findings, this review seeks to support translational efforts toward the development of targeted metabolic interventions and personalized therapeutic strategies in oncology.

Methods

Protocol and Registration: This systematic review was conducted in accordance with PRISMA 2020 guidelines. A comprehensive literature search was conducted using three major electronic databases: PubMed, Scopus, Embase, and Web of Science. The search encompassed all relevant studies published up to August 31, 2025. The protocol was developed prior to data extraction. PROSPERO registration, although attempted, was not accepted as the data extraction had already commenced at the time of submission. No changes were made to the predefined methodology after data extraction began.

Selection Criteria: Studies were considered eligible for inclusion if they met the following criteria: original research articles, including in vitro, in vivo, and clinical studies, that specifically investigated site-specific phosphorylation of PKM2 in the context of cancer. Eligible studies were required to report on the functional, mechanistic, metabolic, or therapeutic relevance of phosphorylated PKM2. Only peer-reviewed, full-text articles published in English were included.

Studies were excluded if they focused solely on other post-translational modifications of PKM2 without providing

relevant phosphorylation data. Additionally, reviews, meta-analyses, editorials, commentaries, conference abstracts, and case reports were excluded. Studies that did not involve cancer or did not establish a clear link between PKM2 phosphorylation and cancer-related outcomes were also excluded. Articles not available in full text or published in languages other than English were not considered for review.

Search Strategy: Search strategy entwined the Medical Subject Headings (MeSH) with free-text terms that related to PKM2, phosphorylation, cancer, and metabolism. Keywords and Boolean operators used were: ("PKM2" OR "pyruvate kinase M2") AND ("phosphorylation" OR "site-specific phosphorylation") AND ("cancer" OR "tumor" OR "neoplasm" OR "malignancy") AND ("metabolism" OR "glycolysis" OR "Warburg effect" OR "metabolic plasticityTo regulate the relevance of the results, the search filters were judiciously used to cover only the full text freely accessible, peer-reviewed original research articles that were conducted in the English language. The search strategy was then narrowed as necessary, on a specific database basis. In addition, reference listings of all the retrieved studies were scrutinized exhaustively by hand to pick up any other shortlisted articles that would be missed during the database search. All the results were subsequently imported into reference management programs, awaiting the exclusion of the duplicates before screening. In PubMed, the following combination of MeSH (Medical Subject Headings) and free-text terms was used to conduct, on a comprehensive basis, a survey of the pertinent literature: ("Pyruvate Kinase" [MeSH] or "PKM2" or "pyruvate kinase M2") and ("Phosphorylation" [MeSH] or "site-specific phosphorylation" or "post-translational phosphorylation") and ("Neoplasms" [MeSH] or "cancer" or "tumor" or "malignancy" or "carcinoma") and ("Neoplastic Cell Metabolism" [MeSH] or "metabolism" or "glycolysis" or "Warburg effect" or "metabolic reprogramming" or "metabolic plasticity").

Selection Process: All retrieved articles were imported into reference management software to remove duplicates automatically. The selection process was carried out in two stages. In the first stage, the author screened the titles and abstracts of all retrieved records to identify potentially eligible studies. In the second stage, full-text articles of shortlisted studies were assessed for inclusion based on predefined eligibility criteria. The screening decisions were independently reviewed by two researchers after completion of the primary screening phase to ensure accuracy and consistency with the predefined eligibility criteria. The reviewers verified inclusion and exclusion decisions. Any discrepancies were resolved through discussion and consensus. The selection process was documented in accordance with the PRISMA 2020 guidelines, and a flow diagram was generated to illustrate study identification, screening, eligibility, and inclusion. [7].

Data collection Process: Data extraction was performed independently by MMA using a standardized data extraction form developed and explicitly piloted for this review, and following completion of the initial data extraction, independently reviewed by two researchers to verify accuracy, completeness, and consistency with the original studies. The form was designed to capture relevant information on study characteristics, methodological details, and key findings. Specifically, the following data were extracted: Study details, Cancer type, Phosphorylation site, Experimental model, Functional outcomes, Mechanistic insights, Clinical relevance.

Risk of Bias Analysis: For preclinical studies, the SYRCLE's Risk of Bias tool was used, which evaluates bias across domains such as random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other biases specific to animal research [8] (Figure 2) [9–38]. For clinical studies, the Cochrane Risk of Bias 2 (RoB 2) tool was used. Each study was graded as having low, moderate, or high risk of bias. Any uncertainties in

risk-of-bias assessment were resolved through discussion with the methodological reviewers [39]. The results of the risk of bias assessments were presented in tabular form and considered in the interpretation of the findings (Figure 3) [6, 40–46].

Effect measures: Given the heterogeneous nature of the included studies, spanning in vitro experiments, in vivo models, and clinical data, effect measures were extracted and reported in accordance with the type of outcome presented. For *in vitro* and *in vivo* studies, effect measures included relative changes in metabolic activity (e.g., glycolysis rate, lactate production), gene/protein expression levels (e.g., fold change in PKM2 or downstream targets), and cellular outcomes such as proliferation, apoptosis, migration, and invasion. These were typically reported as mean ± standard deviation (SD) or standard error (SE), with corresponding p-values or confidence intervals (CIs) where available. For clinical studies, quantitative outcomes such as hazard ratios (HRs), odds ratios (ORs), relative risks (RRs), and their corresponding 95% confidence intervals were extracted to assess associations between site-specific PKM2 phosphorylation and clinical endpoints (e.g., overall survival, disease-free survival, therapeutic response). When multiple studies reported similar quantitative data for a particular phosphorylation site and outcome, the data were qualitatively synthesized and, where appropriate, the direction and magnitude of effect were summarized narratively.

Ethical Statement: Ethical approval was not required for this study as it is a systematic review of previously published studies and did not involve human participants or animal experimentation conducted by the author.

Results

Study Selection and Characteristics

The literature search identified 1,342 records, of which 58 studies fulfilled the inclusion criteria after screening and eligibility assessment. The majority were preclinical (44 studies), complemented by 8 clinical/translational investigations and 6 multi-omics/in silico analyses. Most studies focused on lung, colorectal, breast, glioblastoma, and hepatocellular carcinoma. The included works were published between 2005 and 2025. Key study features are summarized in Supplementary Table 1 [6, 11, 40, 45–53], and the PRISMA flow chart is shown in Figure 1.

Phosphorylation Sites and Functional Roles

The most frequently studied residue was Tyr105 (in 31 studies), where phosphorylation disrupted PKM2 tetramerization, favoring glycolytic reprogramming and biomass accumulation. Elevated Tyr105-PKM2 was consistently associated with aggressive tumor behavior and poor survival in NSCLC, glioblastoma, and colorectal cancer. Ser37 phosphorylation (14 studies), mainly mediated by ERK, facilitated nuclear translocation of PKM2 and activation of oncogenic transcriptional programs such as c-Myc and cyclin D1, contributing to proliferation, epithelial–mesenchymal transition, and chemoresistance.

Thr454 (6 studies) was linked to CDK1-driven cell cycle regulation and stem-like properties in pancreatic and prostate cancer models. Emerging residues such as Ser202/204 were implicated in mitochondrial localization, DNA repair, and redox balance, though findings remain preliminary. A few studies also demonstrated multisite phosphorylation patterns (e.g., Tyr105 + Ser37) that synergistically promoted metabolic plasticity, immune

evasion, and resistance to EGFR inhibitors.

Experimental and Clinical Evidence

Preclinical data consistently showed that phosphorylated PKM2 enhanced aerobic glycolysis, lactate output, anabolic biosynthesis, and redox regulation. In its nuclear form, phospho-PKM2 interacted with β-catenin, HIF-1α, and STAT3, amplifying transcriptional programs supporting tumor growth and immune escape.

In clinical settings, high expression of Tyr105- and Ser37-phosphorylated PKM2 was associated with unfavorable prognosis, higher tumor grade, and resistance to chemotherapy (oxaliplatin, anthracyclines). However, all clinical studies were retrospective with small sample sizes, and no randomized controlled trials were identified.

Risk of Bias and Quality of Evidence

Most preclinical studies lacked randomization, blinding, and adequate sample size justification, while clinical studies showed variability in antibody validation, endpoint reporting, and handling of confounders. Overall, both preclinical and clinical evidence were graded as moderate-to-high risk of bias. Using the GRADE framework, the certainty of evidence was rated moderate for metabolic effects, low for prognostic associations, and very low for predictive or clinical utility in therapy selection. The RoB 2 assessment revealed a moderate risk of bias across most retrospective clinical studies. The primary concerns were confounding factors, incomplete adjustment for clinicopathological variables, and variability in antibody validation for phosphorylated PKM2 detection. No randomized interventional studies were identified, limiting causal inference.

Results of individual studies: A total of 58 individual studies were included in the final synthesis. The findings reflect a consistent focus on the functional impact of site-specific phosphorylation of PKM2 on tumor metabolism, growth, and therapeutic response. The key individual studies are organized below by phosphorylation site and cancer context (Supplementary Table 2).

The funnel plot in Figure 4 displays the distribution of effect sizes from 58 individual studies included in the systematic review. The x-axis represents the estimated effect sizes (e.g., log hazard ratios or standardized mean differences) associated with site-specific PKM2 phosphorylation, while the y-axis indicates the corresponding standard errors. The red dashed vertical line denotes the pooled effect size. The dotted lines represent the pseudo 95% confidence intervals around the pooled estimate, forming the expected funnel shape in the absence of publication bias. Visual asymmetry in the scatter distribution may suggest potential small-study effects or reporting bias. The heterogeneity observed in the funnel plot may partly reflect the inclusion of both preclinical and clinical studies with differing outcome measures, experimental designs, and sample sizes. As these studies do not share a uniform effect metric, the funnel plot should be interpreted as an exploratory visualization rather than a formal assessment of publication bias.

Discussion

This systematic review synthesizes the current evidence on the role of site-specific phosphorylation of pyruvate kinase M2 (PKM2) in cancer metabolism, tumor progression, and therapeutic responsiveness. Across 58 studies, our analysis highlights the central role of PKM2 as a dynamic metabolic regulator whose activity and localization are modulated by phosphorylation at key residues most notably tyrosine 105 (Y105), serine 37 (S37), threonine 45

(Thr45), and tyrosine 148 (Y148) [6, 31, 50]. Phosphorylation at specific PKM2 residues alters its oligomeric state and subcellular localization, thereby influencing cancer cell metabolism [1]. For instance, Y105 phosphorylation disrupts tetramer formation, shifting PKM2 to a dimeric state with lower catalytic activity. This facilitates the accumulation of glycolytic intermediates that fuel anabolic biosynthesis, a hallmark of the Warburg effect [21]. Similarly, S37 phosphorylation promotes PKM2 nuclear translocation, where it functions as a coactivator of oncogenic transcription factors such as β-catenin and HIF-1α [4]. These mechanisms collectively enhance tumor cell adaptability under hypoxic and nutrient-deprived conditions, underscoring phosphorylation-dependent metabolic plasticity as a survival advantage in diverse malignancies.

Several studies link high levels of phosphorylated PKM2 to aggressive tumor phenotypes and poor clinical outcomes. Y105 phosphorylation was associated with increased invasion, epithelial–mesenchymal transition (EMT), and metastasis in hepatocellular, breast, and colorectal cancers [54]. However, most of these findings are derived from preclinical models or small patient cohorts, and their clinical utility remains underexplored. The lack of standardized detection methods and heterogeneous scoring systems across studies also limits comparability and reproducibility.

Our review identifies a growing interest in targeting PKM2 phosphorylation as a therapeutic strategy. Preclinical studies suggest that inhibition of upstream kinases (e.g., FGFR1, ERK, c-Src) or stabilization of the PKM2 tetramer can reverse the pro-tumorigenic effects of phosphorylation [47, 48]. Moreover, phosphorylation status has emerged as a potential predictive biomarker for responsiveness to certain treatments, including tyrosine kinase inhibitors and metabolic modulators. However, few studies have validated these associations in clinical trials, and there is limited consensus on which phosphorylation sites offer the most predictive value [1, 45, 46]. PKM2 phosphorylation and nuclear signaling have also been implicated in several non-malignant diseases characterized by metabolic reprogramming and inflammatory activation (Table 1). These findings indicate that PKM2 phosphorylation reflects a broader adaptive metabolic mechanism rather than a cancer-exclusive event.

Table 1. Roles of PKM2 Phosphorylation in Cancer and Non-Oncological Diseases

Disease Category	**Condition**	**Phosphorylation Mechanism**	**Functional Consequence**	**Clinical/Pathological Relevance**	**Reference**
Cancer	NSCLC / Breast Cancer / Glioblastoma	Tyr105 / Ser37 phosphorylation	Enhanced aerobic glycolysis, Nuclear translocation	Associated with tumor growth, proliferation, and poor prognosis	Hitosugi et al. (2009). Yang et al. (2012). [47,48]
Inflammatory Disease	Sepsis	Nuclear PKM2–STAT3 pathway	Induces pro-inflammatory cytokine production	Drives systemic inflammation	Yu et al. (2014). [55]
Autoimmune Disease	Rheumatoid arthritis	PKM2-mediated metabolic reprogramming	Enhances glycolysis in activated immune cells	Sustains synovial inflammation	Liao et al. (2025). [56]

Dermatological Disease	Psoriasis	Nuclear PKM2 activation	Keratinocyte metabolic shift and proliferation	Contributes to hyperproliferative lesions	Yang et al. (2023). [43]
Infectious Disease	Viral infection/macrophage activation	PKM2 nuclear signaling	Regulates inflammatory gene transcription	Supports immune activation response	Toller-Kawahisa et al. (2025) [57]
Metabolic Disease Context	Chronic inflammatory metabolic states	PKM2-dependent glycolytic reprogramming	Alters glucose metabolism in immune cells	Associated with sustained inflammation	Xie et al. (2016)

Despite the promising findings, the overall certainty of the evidence remains low to very low, primarily due to the predominance of in vitro and animal studies, variability in study design, and potential publication bias. Many studies lacked adequate control groups, were not blinded, or did not assess long-term functional outcomes. Furthermore, the interactions between multiple post- translational modifications on PKM2 and their collective impact on tumor behavior remain poorly understood. Few studies addressed the effects of co-occurring genetic mutations, tumor heterogeneity, or tumor microenvironmental factors, all of which could modulate the functional impact of PKM2 phosphorylation. The funnel plot analysis further reflects this methodological heterogeneity. The visual dispersion and asymmetry likely arise from the combined inclusion of mechanistic in vitro studies, animal models, and retrospective clinical cohorts, each characterized by distinct outcome measures and sample size structures. As these study types do not share uniform effect metrics, the funnel plot should be interpreted cautiously as an exploratory visualization rather than definitive evidence of publication bias. Future analyses restricted to homogeneous clinical endpoints may provide more reliable bias assessment.

To advance this field, future research should focus on standardizing methodologies for detecting site-specific PKM2 phosphorylation in clinical samples. Elucidating mechanistic pathways downstream of each phosphorylation site using CRISPR-based gene editing and phosphomimetic models. Integrating PKM2 phosphorylation status into clinical trials, especially those targeting metabolic pathways or using biomarker-driven patient selection. Exploring combinatorial targeting strategies that inhibit PKM2 phosphorylation alongside immunotherapy or chemotherapy.

Conclusion

Site-specific phosphorylation of PKM2 plays a critical role in promoting metabolic reprogramming, tumor progression, and therapeutic resistance across multiple cancer types. While the existing preclinical data are compelling, the translation of these findings into clinical practice is still in its infancy. Rigorous validation and prospective studies are essential to determine whether PKM2 phosphorylation can serve as a reliable biomarker or therapeutic target in precision oncology. Given its involvement in inflammatory and autoimmune conditions, disease-specific validation is required before clinical implementation.

Declaration and Statements

Acknowledgements: The author gratefully acknowledges Najran University for providing research facilities. The author also thanks colleagues in the Clinical Laboratory Sciences Department, Dr. Elhashimi Eltayb Hassan and Dr. Omer Mohamed Shoaib, for their valuable feedback on the study protocol and methodological procedures.

Funding: The author declares that no financial support was received for this research.

Conflict of Interest: The author declares no competing interests.

Data availability statement: All data generated or analysed during this study are included in this manuscript or supplementary information files.

Authors Contribution: The author confirms sole responsibility for the conception, design, analysis, drafting, and finalization of the manuscript. All aspects of the work were performed independently by the author.

References

1. Dong, G. et al. PKM2 and cancer: The function of PKM2 beyond glycolysis (Review). *Oncol. Lett.* **11**, 1980-1986; 10.3892/OL.2016.4168 (2016).
2. Warburg, O. On the origin of cancer cells. *Science* **123**, 309-314; 10.1126/SCIENCE.123.3191.309 (1956).
3. Prakasam, G., Iqbal, M. A., Bamezai, R. N. K. & Mazurek, S. Posttranslational modifications of pyruvate kinase M2: tweaks that benefit cancer. *Front. Oncol.* **8**, 22; 10.3389/FONC.2018.00022 (2018).
4. Yang, W. et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. *Nature* **480**, 118-122; 10.1038/NATURE10598 (2011).
5. Yang, W. & Lu, Z. Regulation and function of pyruvate kinase M2 in cancer. *Cancer Lett.* **339**, 153-158; 10.1016/J.CANLET.2013.06.008 (2013).
6. Wang, C. et al. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells. *Cell Death Dis.* **12**, 4342; 10.1038/S41419-021-04342-Y (2021).
7. Fernandes, P. M., Kinkead, J., McNae, I., Michels, P. A. M. & Walkinshaw, M. D. Biochemical and transcript level differences between the three human phosphofructokinases show optimisation of each isoform for specific metabolic niches. *Biochem. J.* **477**, 4425-4441; 10.1042/BCJ20200656 (2020).
8. Haddaway, N. R., Page, M. J., Pritchard, C. C. & McGuinness, L. A. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open. *Campbell Syst. Rev.* **18**, e1230; 10.1002/CL2.1230 (2022).
9. Voss, D. M. et al. PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma. *J. Biol. Chem.* **301**, 108345; 10.1016/J.JBC.2025.108345 (2025).

10. Wei, J. et al. Casticin inhibits proliferation of non-small cell lung cancer cells through regulating reprogramming of glucose metabolism. *Phytomedicine* **136**, 156278; 10.1016/J.PHYMED.2024.156278 (2025).
11. Li, Q. et al. NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasis. *J. Exp. Clin. Cancer Res.* **44**, 90; 10.1186/S13046-025-03343-5 (2025).
12. Wang, J. et al. A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles. *Theranostics* **15**, 3439-3461; 10.7150/THNO.103722 (2025).
13. Liu, S. et al. Ginseng Glucosyl Oleanolate Suppresses Cervical Cancer via Simultaneous Inhibition of Glycolysis and Oxidative Phosphorylation In Vivo/Vitro. *J. Agric. Food Chem.* **73**, 18746-18762; 10.1021/ACS.JAFC.5C01471 (2025).
14. Zhan, W. et al. BRG1 inhibits glycolysis by promoting SHP1-mediated dephosphorylation of PKM2 in non-small cell lung cancer. *Oncogenesis* **14**, 577; 10.1038/S41389-025-00577-Y (2025).
15. Wang, Y. et al. PKM2 functions as a histidine kinase to phosphorylate PGAM1 and increase glycolysis shunts in cancer. *EMBO J.* **43**, 2368-2396; 10.1038/S44318-024-00110-8 (2024).
16. Olea-Flores, M., Sharma, T., Verdejo-Torres, O., DiBartolomeo, I. & Thompson, P. R. Muscle-specific pyruvate kinase isoforms, PKM1 and PKM2, regulate mammalian SWI/SNF proteins and histone 3 phosphorylation during myoblast differentiation. *FASEB J.* **38**, e400784; 10.1096/FJ.202400784R (2024).
17. Chen, X. et al. SYK promotes the formation of neutrophil extracellular traps by inducing PKM2 nuclear translocation and promoting STAT3 phosphorylation to exacerbate hepatic. *Mol. Med.* **30**, 907; 10.1186/S10020-024-00907-7 (2024).
18. Chen, J. et al. MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration. *Nat. Commun.* **15**, 49221; 10.1038/S41467-024-49221-0 (2024).
19. Li, C. et al. A novel role for the ROS-ATM-Chk2 axis mediated metabolic and cell cycle reprogramming in the M1 macrophage polarization. *Redox Biol.* **70**, 103059; 10.1016/J.REDOX.2024.103059 (2024).
20. Wang, T. et al. Cryptotanshinone suppresses ovarian cancer via simultaneous inhibition of glycolysis and oxidative phosphorylation. *Biomed. Pharmacother.* **170**, 115956; 10.1016/J.BIOPHA.2023.115956 (2024).
21. Zhou, Z. et al. ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer. *Oncogene* **43**, 1769-1778; 10.1038/S41388-024-03035-Y (2024).
22. Chen, T. et al. AKT1 phosphorylation of cytoplasmic ME2 induces a metabolic switch to glycolysis for tumorigenesis. *Nat. Commun.* **15**, 44772; 10.1038/S41467-024-44772-8 (2024).
23. Tian, M. et al. TIPE drives a cancer stem-like phenotype by promoting glycolysis via PKM2/HIF-1α axis in melanoma. *Elife* **13**, e92741; 10.7554/ELIFE.92741 (2024).
24. Peng, C. et al. KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2. *Acta Pharm. Sin. B* **14**, 2959-2976;

10.1016/J.APSB.2024.04.024 (2024).

25. Zhang, Y. et al. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. *Cell Metab.* **36**, 193-208.e8; 10.1016/J.CMET.2023.12.003 (2024).
26. Liu, J. et al. Calcium channel α2δ1 is essential for pancreatic tumor-initiating cells through sequential phosphorylation of PKM2. *Cell Mol. Gastroenterol. Hepatol.* **15**, 373-392; 10.1016/J.JCMGH.2022.10.006 (2023).
27. Lai, X. et al. Protein kinase C epsilon promotes de novo lipogenesis and tumor growth in prostate cancer cells by regulating the phosphorylation and nuclear translocation of PKM2. *Exp. Cell Res.* **422**, 113427; 10.1016/J.YEXCR.2022.113427 (2023).
28. Liang, N. et al. Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy. *Biomed. Res. Int.* **2023**, 3375109; 10.1155/2023/3375109 (2023).
29. Pak, J. N. et al. Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells. *Phytother. Res.* **37**, 4224-4235; 10.1002/PTR.7903 (2023).
30. Lee, Y. B. et al. Multiple functions of pyruvate kinase M2 in various cell types. *J. Cell Physiol.* **237**, 128-148; 10.1002/JCP.30536 (2022).
31. Jiang, Y. et al. Aurora A–mediated pyruvate kinase M2 phosphorylation promotes biosynthesis with glycolytic metabolites and tumor cell cycle progression. *J. Biol. Chem.* **298**, 102561; 10.1016/J.JBC.2022.102561 (2022).
32. Pu, F. et al. LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis. *Int. J. Oncol.* **60**, 5334; 10.3892/IJO.2022.5334 (2022).
33. Song, J. et al. A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5. *J. Exp. Clin. Cancer Res.* **41**, 171; 10.1186/S13046-022-02374-6 (2022).
34. Wang, Y. et al. EGF promotes PKM2 O-GlcNAcylation by stimulating O-GlcNAc transferase phosphorylation at Y976 and their subsequent association. *J. Biol. Chem.* **298**, 102340; 10.1016/J.JBC.2022.102340 (2022).
35. Zhang, Z. et al. Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis. *Exp. Hematol. Oncol.* **11**, 334; 10.1186/S40164-022-00334-6 (2022).
36. Cao, F. et al. Girdin promotes tumorigenesis and chemoresistance in lung adenocarcinoma by interacting with PKM2. *Cancers* **14**, 5688; 10.3390/CANCERS14225688 (2022).
37. Jia, Y. et al. Crosstalk between hypoxia-sensing ULK1/2 and YAP-driven glycolysis fuels pancreatic ductal adenocarcinoma development. *Int. J. Biol. Sci.* **17**, 2772-2794; 10.7150/IJBS.60018 (2021).
38. Patel, M. S., Mahmood, S., Jung, J. & Rideout, T. C. Reprogramming of aerobic glycolysis in non-transformed mouse liver with pyruvate dehydrogenase complex deficiency. *Physiol. Rep.* **9**, e14684; 10.14814/PHY2.14684 (2021).
39. McGuinness, L. A. & Higgins, J. P. T. Risk-of-bias VISualization (robvis): an R package and Shiny

web app for visualizing risk-of-bias assessments. *Res. Synth. Methods* **12**, 55-61; 10.1002/JRSM.1411 (2021).

40. Zhou, B. et al. SHP2 mutations promote glycolysis and inhibit apoptosis via PKM2/hnRNPK signaling in colorectal cancer. *iScience* **27**, 110462; 10.1016/J.ISCI.2024.110462 (2024).
41. Wang, B. et al. LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination. *Cell Death Dis.* **15**, 6564; 10.1038/S41419-024-06564-2 (2024).
42. Yang, Y. et al. Small ankyrin 1 (sANK1) promotes docetaxel resistance in castration-resistant prostate cancer cells by enhancing oxidative phosphorylation. *FEBS Open Bio* **13**, 257-269; 10.1002/2211-5463.13535 (2023).
43. Yang, L. et al. Nuclear translocation of PKM2 mediates keratinocyte metabolic reprogramming in psoriasis. *Exp. Dermatol.* **32**, 1960-1970; 10.1111/EXD.14922 (2023).
44. Zhao, G. et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. *Signal Transduct. Target Ther.* **7**, 1096; 10.1038/S41392-022-01096-7 (2022).
45. Li, L. et al. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. *Oncotarget* **8**, 33047-33063; 10.18632/ONCOTARGET.16523 (2017).
46. Mohammad, G. H., Olde Damink, S. W. M., Malago, M., Dhar, D. K. & Pereira, S. P. Pyruvate kinase M2 and lactate dehydrogenase A are overexpressed in pancreatic cancer and correlate with poor outcome. *PLoS One* **11**, e0151635; 10.1371/JOURNAL.PONE.0151635 (2016).
47. Hitosugi, T. et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. *Sci. Signal.* **2**, ra73; 10.1126/SCISIGNAL.2000431 (2009).
48. Yang, W. et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. *Nat. Cell Biol.* **14**, 1295-1304; 10.1038/NCB2629 (2012).
49. Zhao, G. et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. *Mol. Cancer Ther.* **10**, 2200-2210; 10.1158/1535-7163.MCT-11-0306 (2011).
50. Lee, S. A., Ho, C., Troxler, M., Lin, C. Y. & Chung, S. H. Non-metabolic functions of PKM2 contribute to cervical cancer cell proliferation induced by the HPV16 E7 oncoprotein. *Viruses* **13**, 433; 10.3390/V13030433 (2021).
51. Liang, J. et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. *Cell Res.* **27**, 329-351; 10.1038/CR.2016.159 (2017).
52. Wang, Y. et al. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 13732-13737; 10.1073/PNAS.1704145115 (2017).
53. Zerdes, I. et al. STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer. *Cancers* **11**, 1479; 10.3390/CANCERS11101479 (2019).
54. Zhou, Z. et al. Oncogenic kinase–induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem–like cells. *Cancer Res.* **78**, 2248-2261; 10.1158/0008-5472.CAN-17-2726 (2018).
55. Yu, S., Pei, S., Zhang, M., Gao, S., Chen, J., Duan, L., ... & Huang, Y. (2024). PKM2-mediated

STAT3 phosphorylation promotes acute liver failure via regulating NLRP3-dependent pyroptosis. *Communications Biology*, *7*(1), 1694. https://doi.org/10.1038/s42003-024-07227-w

56. Liao, H. Y., Zhang, G. H., Zheng, J. X., Lu, J. Y., Hao, J. Y., Tan, M., ... & Shen, H. L. (2025). Pyruvate kinase M2 (PKM2) regulates rheumatoid arthritis by mediating glycolysis reprogramming through the Akt/mTOR pathway. *The International Journal of Biochemistry & Cell Biology*, 106870. https://doi.org/10.1016/j.biocel.2025.106870
57. Toller-Kawahisa, J. E., Viacava, P. R., Palsson-McDermott, E. M., Nascimento, D. C., Cervantes-Silva, M. P., O'Carroll, S. M., ... & Alves-Filho, J. C. (2025). Metabolic reprogramming of macrophages by PKM2 promotes IL-10 production via adenosine. *Cell Reports*, *44*(1). 10.1016/j.celrep.2024.115172
58. Xie, M., Yu, Y., Kang, R., Zhu, S., Yang, L., Zeng, L., ... & Tang, D. (2016). PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. *Nature communications*, *7*(1), 13280. https://doi.org/10.1038/ncomms13280

Figure Legends:

Figure 1: PRISMA Flow Diagram

Figure 2: SYRCLE's Risk of Bias for preclinical studies. **(A)** Study 1-30; **(B)** Studies 31-50; **(C)** Summary plot

Figure 3: ROB analysis of clinical articles

Figure 4. Funnel Plot of Included Studies Evaluating Site-specific PKM2 Phosphorylation in Cancer.


SITE-SPECIFIC PKM2 PHOSPHORYLATION IN CANCER
Tyr105
Ser37
Thr454
Tyr105
Ser37
Thr454
METABOLIC FUNCTIONS
TUMOR PROGRESSION
METABOLIC FUNCTIONS
NON-METABOLIC FUNCTIONS
Enhanced Glycolysis
Glucose
Pyruvate
Lactate
Proliferation
EMT
THERAPY RESISTANCE
Nucleus



PRISMA Flow Diagram.



SYRCLE's Risk of Bias for preclinical studies. (A) Study 1-30; (B) Studies 31-50; (C) Summary plot



ROB analysis of clinical articles



Funnel Plot of Included Studies Evaluating Site-specific PKM2 Phosphorylation in Cancer